Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06997029 | A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors | PHASE1 | RECRUITING | 234 | — | — | Aug 1, 2025 | Dec 14, 2028 | Apr 21, 2026 | 21 | United States, Denmark +1 |
| Arm | Type | Description |
|---|---|---|
| Part 1A Monotherapy Dose Escalation | EXPERIMENTAL | - |
| Part 1B Combination Dose Escalation | EXPERIMENTAL | - |
| Part 1C Monotherapy Pharmacodynamic (PD) Sub-study | EXPERIMENTAL | - |
| Part 2A Monotherapy Dose Expansion | EXPERIMENTAL | - |
| Part 2B Combination Dose Expansion | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-986500 | DRUG | Specified dose of specified days |
| Palbociclib | DRUG | Specified dose on specified days |
| Fulvestrant | DRUG | Specified dose on specified days |
Inclusion Criteria: * Participants must be ≥ 18 years of age. * Participants must have histologically confirmed diagnosis of a locally advanced, unresectable, or metastatic solid tumor malignancy. * Participants must have a measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab, V503, GARDASIL |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| AstraZeneca PLC | AZN | 1 | — | Trastuzumab deruxtecan |